SCHEMBL3101359

SCHEMBL3101359

COc1ccc(Cn2nc(-c3ccc(C(=O)N4CCOCC4)cc3)c3c(Oc4ccc(NC(=O)c5ccnn(-c6ccc(F)cc6)c5=O)cc4F)ccnc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
AXL P30530 20/20 0.50
MERTK Q12866 20/20 0.50
MET P08581 19/20 0.50
TYRO3 Q06418 16/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3104308 0.92 AXL (0.57) AXLMERTKMETTYRO3
SCHEMBL3101695 0.89 MET (0.38) AXLMERTKMETTYRO3
SCHEMBL3100095 0.88 AXL (0.55) AXLMERTKMETTYRO3
SCHEMBL3104234 0.88 AXL (0.51) AXLMERTKMETTYRO3
SCHEMBL3101814 0.87 AXL (0.54) AXLMERTKMETTYRO3
SCHEMBL3112869 0.86 MET (0.58) AXLMERTKMETTYRO3
SCHEMBL3109135 0.86 AXL (0.54) AXLMERTKMETTYRO3
SCHEMBL1946244 0.85 AXL (0.53) AXLMERTKMETTYRO3
SCHEMBL30693661 0.84 AXL (0.58) AXLMERTKMETTYRO3
SCHEMBL3103995 0.84 AXL (0.58) AXLMERTKMETTYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2010-10-07 US disclosed
US-7723330-B2 Heterobicyclic pyrazole compounds and methods of use ARRAY BIOPHARMA INC. (US) 2010-05-25 US disclosed
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use GENENTECH, INC. 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ROR1, CYP11B1, CYP11B2 AXL 117/4885MERTK 285/4885MET 357/4885
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use ROR1, CYP11B1, CYP11B2 AXL 117/4885MERTK 285/4885MET 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.